With enhanced efficacy due to a bispecific mode of action and an excellent
safety profile partly due to the absence of an Fc region, TandAbs represent
a strong front runner in the race to develop alternatives to first-generation
antibody therapeutics.

Keywords: With enhanced efficacy due to a bispecific mode of action and an excellent
safety profile partly due to the absence of an Fc region, TandAbs represent
a strong front runner in the race to develop alternatives to first-generation
antibody therapeutics.